Physician profile
Saurabh Singh
NPI 1275790925
$1,675,654.50
in general payments reported to CMS, 2019-2025
47 companies · $516K in 2025
The $516K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $27K · 2021: $34K · 2022: $205K · 2023: $421K · 2024: $406K · 2025: $516K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.1M · Consulting Fee: $80K · Travel and Lodging: $78K · Food and Beverage: $47K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $43K · Honoraria: $18K · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,076,653.14 |
| Consulting Fee | $80,450.27 |
| Travel and Lodging | $77,874.60 |
| Food and Beverage | $46,595.04 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $43,099.29 |
| Honoraria | $18,400.00 |
| Education | $337.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291,417.20 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $252,630.17 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Genzyme Corporation | $193,724.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $173,160.48 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $156,303.07 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Regeneron Healthcare Solutions, INC. | $107,914.27 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $99,923.38 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $82,720.72 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $66,094.58 | 2019-2025 | Ilumya, Winlevi, Odomzo |
| Arcutis Biotherapeutics, INC. | $61,281.04 | 2023-2025 | Zoryve |
| Botanix Sb INC | $42,492.21 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $33,955.60 | 2022-2023 | Tremfya |
| Pfizer INC. | $31,355.64 | 2019-2025 | |
| Organon LLC | $20,451.94 | 2023-2025 | Vtama, Hadlima |
| Janssen Biotech, INC. | $12,166.21 | 2019-2025 | Tremfya |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.